Literature DB >> 16611403

The role of c-KIT in tumorigenesis: evaluation in canine cutaneous mast cell tumors.

Joshua D Webster1, Vilma Yuzbasiyan-Gurkan, John B Kaneene, RoseAnn Miller, James H Resau, Matti Kiupel.   

Abstract

The c-KIT proto-oncogene has been implicated in the pathogenesis of several neoplastic diseases, including gastrointestinal stromal tumors and mastocytosis in humans, and mast cell tumors (MCTs) in canines. Cutaneous MCTs are common neoplasms in dogs and have a variable biologic behavior. The goal of this study was to define the prognostic significance of c-KIT mutations identified in canine MCTs and the associations between c-KIT mutations, KIT localization, and KIT expression levels. Microdissection and polymerase chain reaction were performed on 60 MCTs to identify c-KIT mutations. Anti-KIT antibodies were used for immunohistochemical evaluation of KIT localization. Forty-two MCTs were included in a tissue microarray, and KIT expression was quantified using immunofluorescence. Canine MCTs with c-KIT mutations were significantly associated with an increased incidence of recurrent disease and death. c-KIT mutations were also significantly associated with aberrant protein localization; however, the level of KIT expression did not correlate with either c-KIT mutations or changes in protein localization. Considering the high prevalence of canine MCTs and the central role of c-KIT in the tumorigenesis of certain tumors, canine MCTs are an excellent model for characterizing the role of c-KIT in neoplastic diseases and is a potential target for novel therapeutic agents in clinical trials.

Entities:  

Mesh:

Substances:

Year:  2006        PMID: 16611403      PMCID: PMC1578516          DOI: 10.1593/neo.05622

Source DB:  PubMed          Journal:  Neoplasia        ISSN: 1476-5586            Impact factor:   5.715


  56 in total

Review 1.  Mast cell disease.

Authors:  I Schneider; R A Schwartz
Journal:  Cutis       Date:  1997-02

2.  Paraffin section detection of the c-kit gene product (CD117) in human tissues: value in the diagnosis of mast cell disorders.

Authors:  D A Arber; R Tamayo; L M Weiss
Journal:  Hum Pathol       Date:  1998-05       Impact factor: 3.466

3.  Spontaneous canine mast cell tumors express tandem duplications in the proto-oncogene c-kit.

Authors:  C A London; S J Galli; T Yuuki; Z Q Hu; S C Helfand; E N Geissler
Journal:  Exp Hematol       Date:  1999-04       Impact factor: 3.084

4.  Gain-of-function mutations of c-kit in human gastrointestinal stromal tumors.

Authors:  S Hirota; K Isozaki; Y Moriyama; K Hashimoto; T Nishida; S Ishiguro; K Kawano; M Hanada; A Kurata; M Takeda; G Muhammad Tunio; Y Matsuzawa; Y Kanakura; Y Shinomura; Y Kitamura
Journal:  Science       Date:  1998-01-23       Impact factor: 47.728

5.  Expression of the KIT protein (CD117) in primary cutaneous mast cell tumors of the dog.

Authors:  Rosario Preziosi; Maria Morini; Giuseppe Sarli
Journal:  J Vet Diagn Invest       Date:  2004-11       Impact factor: 1.279

6.  Expression of stem cell factor receptor (c-kit) by the malignant mast cells from spontaneous canine mast cell tumours.

Authors:  C A London; W C Kisseberth; S J Galli; E N Geissler; S C Helfand
Journal:  J Comp Pathol       Date:  1996-11       Impact factor: 1.311

7.  Identification of a point mutation in the catalytic domain of the protooncogene c-kit in peripheral blood mononuclear cells of patients who have mastocytosis with an associated hematologic disorder.

Authors:  H Nagata; A S Worobec; C K Oh; B A Chowdhury; S Tannenbaum; Y Suzuki; D D Metcalfe
Journal:  Proc Natl Acad Sci U S A       Date:  1995-11-07       Impact factor: 11.205

8.  Clustering of activating mutations in c-KIT's juxtamembrane coding region in canine mast cell neoplasms.

Authors:  Y Ma; B J Longley; X Wang; J L Blount; K Langley; G H Caughey
Journal:  J Invest Dermatol       Date:  1999-02       Impact factor: 8.551

9.  Autocrine growth of small cell lung cancer mediated by coexpression of c-kit and stem cell factor.

Authors:  G W Krystal; S J Hines; C P Organ
Journal:  Cancer Res       Date:  1996-01-15       Impact factor: 12.701

10.  Prevalence of KIT expression in human tumors.

Authors:  Philip Th Went; Stephan Dirnhofer; Marcel Bundi; Martina Mirlacher; Peter Schraml; Sara Mangialaio; Sasa Dimitrijevic; Juha Kononen; Alessandro Lugli; Ronald Simon; Guido Sauter
Journal:  J Clin Oncol       Date:  2004-11-15       Impact factor: 44.544

View more
  40 in total

1.  Diagnostic procedures for improving of the KIT (CD117) expressed allele burden for the liver metastases from uterus mast cell tumors: prognostic value of the metastatic pattern and tumor biology.

Authors:  Ehsan Hosseini; Behnam Pedram; Ali Mohammad Bahrami; Seyed Rashid Touni; Hamed Zamankhan Malayeri; Aram Mokarizadeh; Mehdi Pourzaer; Maryam Pourzaer; Shahram Zehtabian; Sheida Mohajer; Sharareh Ahmadi
Journal:  Tumour Biol       Date:  2014-10-15

Review 2.  FLT3-ITD and its current role in acute myeloid leukaemia.

Authors:  Francisco Alejandro Lagunas-Rangel; Venice Chávez-Valencia
Journal:  Med Oncol       Date:  2017-05-03       Impact factor: 3.064

3.  KTN0158, a Humanized Anti-KIT Monoclonal Antibody, Demonstrates Biologic Activity against both Normal and Malignant Canine Mast Cells.

Authors:  Cheryl A London; Heather L Gardner; Sarah Rippy; Gerald Post; Krista La Perle; Linda Crew; Lori Lopresti-Morrow; Andrew J Garton; Gerald McMahon; Theresa M LaVallee; Richard Gedrich
Journal:  Clin Cancer Res       Date:  2016-11-04       Impact factor: 12.531

4.  Genomic profiling of canine mast cell tumors identifies DNA copy number aberrations associated with KIT mutations and high histological grade.

Authors:  Hiroyuki Mochizuki; Rachael Thomas; Scott Moroff; Matthew Breen
Journal:  Chromosome Res       Date:  2017-01-05       Impact factor: 5.239

5.  Canine and human gastrointestinal stromal tumors display similar mutations in c-KIT exon 11.

Authors:  Emmalena Gregory-Bryson; Elizabeth Bartlett; Matti Kiupel; Schantel Hayes; Vilma Yuzbasiyan-Gurkan
Journal:  BMC Cancer       Date:  2010-10-15       Impact factor: 4.430

6.  Detection of novel polymorphisms in the ckit gene of canine patients with lymphoma, melanoma, haemangiosarcoma, and osteosarcoma.

Authors:  Irina Gramer; Martin Kessler; Joachim Geyer
Journal:  Vet Res Commun       Date:  2016-03-12       Impact factor: 2.459

7.  Neoplasia: the second decade.

Authors:  Alnawaz Rehemtulla
Journal:  Neoplasia       Date:  2008-12       Impact factor: 5.715

8.  Galectin-3 as a potential therapeutic target in tumors arising from malignant endothelia.

Authors:  Kim D Johnson; Olga V Glinskii; Valeri V Mossine; James R Turk; Thomas P Mawhinney; Douglas C Anthony; Carolyn J Henry; Virginia H Huxley; Gennadi V Glinsky; Kenneth J Pienta; Avraham Raz; Vladislav V Glinsky
Journal:  Neoplasia       Date:  2007-08       Impact factor: 5.715

9.  The novel HSP90 inhibitor STA-9090 exhibits activity against Kit-dependent and -independent malignant mast cell tumors.

Authors:  Tzu-Yin Lin; Misty Bear; Zhenjian Du; Kevin P Foley; Weiwen Ying; James Barsoum; Cheryl London
Journal:  Exp Hematol       Date:  2008-07-26       Impact factor: 3.084

10.  C-kit and its ligand stem cell factor: potential contribution to prostate cancer bone metastasis.

Authors:  Christoph Wiesner; Sanaa M Nabha; Emanuel Burck Dos Santos; Hamilto Yamamoto; Hong Meng; Sebastian W Melchior; Fernando Bittinger; Joachim W Thüroff; Robert L Vessella; Michael L Cher; R Daniel Bonfil
Journal:  Neoplasia       Date:  2008-09       Impact factor: 5.715

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.